Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
119,747,899
-
Total 13F shares
-
58,449,543
-
Share change
-
-12,189,429
-
Total reported value
-
$61,369,526
-
Put/Call ratio
-
112%
-
Price per share
-
$1.05
-
Number of holders
-
102
-
Value change
-
-$207,123,774
-
Number of buys
-
59
-
Number of sells
-
82
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q4 2023
As of 31 Dec 2023,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,449,543 shares.
The largest 10 holders included
BlackRock Inc., CITADEL ADVISORS LLC, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, MILLENNIUM MANAGEMENT LLC, Rock Springs Capital Management LP, ACADIAN ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., Velan Capital Investment Management LP, and TANG CAPITAL MANAGEMENT LLC.
This page lists
102
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.